A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager ... Risks and uncertainties that contribute to the ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data ...

Research about whether CBD improves fibromyalgia symptoms is sparse. However, read on to learn about existing evidence and ...

And since back pain often rears its ugly head while you’re trying to drift off to sleep or ease yourself out of bed in the ...

If our first album was about running away, this one is about staying put and reflecting;” posits Cian Godfrey from Somebody’s Child as they announce upcoming album, When Youth Fades Away, “It’s about ...

Interior designer Mehnaz Khan doesn’t just use color — she lives and breathes it. Whether she’s selecting the perfect shade for a client’s living room or experimenting with hues on her own canvas, ...

The search for convenience and efficiency has never been more critical in today’s fast-paced world. Many people rely on ...

Atea has selected and is manufacturing a fixed dose combination (FDC) tablet for its upcoming Phase 3 program ... In the trial, bemnifosbuvir was shown to be generally safe and well tolerated. The ...

ST. LOUIS, November 07, 2024 -- ( BUSINESS WIRE )--Nerdy Inc. (NYSE: NRDY) today announced financial results for the third quarter ended September 30, 2024.

General and administrative expense for the three months ended September 30, 2024, totaled $11.9 million compared to $12.2 million for the three months ended September 30, 2023, a decrease of ...